Research Studies

What if you could use your phone to improve your schizophrenia symptoms as part of your treatment plan? Learn about the Enspirus research study of an investigational smartphone app for adults with schizophrenia. While in this study, you will continue taking your current schizophrenia medication.

To pre-qualify for this study, you must:

• Be 18 years of age or older
• Have been diagnosed with schizophrenia
• Be experiencing negative symptoms of schizophrenia such as:
  • Emotional withdrawal
  • pathy
  • Reduced social interaction and feelings of pleasure in everyday life
• Be taking antipsychotic medication for at least 12 weeks prior to beginning the study
• Have a smartphone and email address
   

If you would like further information or you’re interested in taking part please contact us at [email protected].

Learn More

We invite you to participate in a research study aimed at improving family relations and mental health symptoms. Groups will be offered virtually and in person. Dates/Times TBD.

Psychotherapy groups consist of 5 modules: 

• Family/Collectivism 
• Psychoeducation 
• Religion/Spirituality/Philosophical Beliefs 
• Communication Skills 
• Problem-Solving Skills 
  
  

Each of these modules consists of 3 sessions and each session is one hour, once a week. 

Inclusion Criteria:

• 18 years or older.
• Person with living experience of psychosis or relative or friend of someone with psychosis. 
• Affiliated with the INSPIRE Clinic.
  
  

If you are interested in participating, please contact the Principal Investigator, Dr. Olivia Altamirano or inform your INSPIRE Provider. Contact Information:  Phone Number: (650) 736-1443, Email: [email protected]

For complaints, concerns, or Participant's rights, contact: 1-866-680-2906

Stanford researchers are recruiting adults with schizophrenia for a clinical trial adding an additional medicine to their existing antipsychotic treatment.  with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of a muscarinic drug adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia.   An initial six week trial may be optionally followed by 52 weeks of open-label study.  If you would like further information or you’re interested in taking part please contact us at  [email protected].

Learn More: Arise KAR-012 and KAR-013

Stanford researchers are recruiting teen participants with schizophrenia, schizophreniform, or bipolar disorder who are either currently treated with olanzapine, or if treated with another antipsychotic, the subject has had an inadequate response. The purpose of this study is to find out whether a study drug, LYVALBI (an approved FDA medication of olanzapine/samidorphan), is safe and effective in reducing weight gain in teen participants taking antipsychotics. A 52 week trial may be optionally extended to study long term safety.  If you would like further information or you’re interested in taking part please contact us at [email protected].

Learn More

Stanford researchers are recruiting healthy controls and participants with an onset of schizophrenia within the last 5 years for a basic research study involving a pET scan.  The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. We are measuring the synaptic density in the living human brain and exploring the theory that the pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development.  For further information or if you are interested in taking part please contact us at [email protected]

Learn More

Stanford researchers are recruiting participants who are already participating in Imaging Synapses With [11C] UCB-J in the Human Brain for participation in basic research exploring the role of the complement immune system in the development of schizophrenia.  The purpose of this study is to compare immune system proteins found in the blood of patients with and without psychosis, to determine if functional differences are present that may shed light on biochemical and genetic differences in schizophrenia.  Participants would do a single blood draw, usually done during the imaging scan.  If you would like further information or you’re interested in taking part please contact us at [email protected].

Learn More

Stanford researchers are working with UC Davis to recruit patients with schizophrenia to build a California early psychosis network using a core assessment battery of surveys delivered by iPad during a normal clinical visit.  The aim of this study is to measure the Duration of Untreated Psychosis (DUP) and hopefully standardize best practices for first onset of psychosis throughout the state in community settings. The proposed California network will contribute systematically collected outcomes data from community and university early psychosis clinics, to enhance the development of a national early psychosis network, supported by the NIMH EPINET program.  If you would like further information or you're interested in taking part please contact your clinician during your regular INSPIRE appointment.

Learn More

Stanford researchers are working with UC San Francisco to recruit patients with schizophrenia, schizoaffective disorder, or bipolar disorder for a study on the impact of a ketogenic diet on mental and physical health.  The premise of the work is based on recent evidence that ketogenic diets improve dynamic neural network instability, related to cognitive deficits, aging, metabolic syndrome, and Type 2 diabetes.

Learn More

A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TD

Stanford researchers are participating in a registry study to follow the natural history of tardive dyskinesia (TD) and optionally to investigate the real-world effectiveness of deutetrabenazine (FDA-approved medicine AUSTEDO) on treating TD.  This trial is closed to new participants.

Learn More